Standout Papers
- Diagnosis of gastrointestinal stromal tumors: A consensus approach (2002)
- PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors (2003)
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor (2003)
- Biology of Gastrointestinal Stromal Tumors (2004)
- Gastrointestinal stromal tumour (2007)
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT (2008)
- PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib (2005)
- Gastrointestinal stromal tumours: origin and molecular oncology (2011)
- Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors (2006)
- Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor (2008)
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205 (2010)
- The Novel Marker, DOG1, Is Expressed Ubiquitously in Gastrointestinal Stromal Tumors Irrespective of KIT or PDGFRA Mutation Status (2004)
- Gastrointestinal stromal tumour (2013)
- Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels (2017)
- Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group (2008)
Immediate Impact
21 by Nobel laureates 24 from Science/Nature 88 standout
Citing Papers
TGF-β signaling in health and disease
2023 Standout
Biliary tract cancer
2021 Standout
Works of Christopher L. Corless being referenced
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
2015
Loss of transforming growth factor-β type II receptor promotes metastatic head-and-neck squamous cell carcinoma
2006
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Christopher L. Corless | 16635 | 14883 | 9665 | 318 | 30.3k | |
| Michael C. Heinrich | 17093 | 16713 | 8229 | 373 | 31.5k | |
| Leslie H. Sobin | 14073 | 10256 | 13948 | 215 | 30.9k | |
| Robert G. Maki | 17885 | 7745 | 5137 | 377 | 25.7k | |
| Brian P. Rubin | 10841 | 7150 | 5075 | 273 | 18.7k | |
| Raf Sciot | 11789 | 4398 | 4077 | 544 | 23.7k | |
| Jason L. Hornick | 11221 | 2279 | 4978 | 479 | 24.0k | |
| Pancras C.W. Hogendoorn | 14667 | 2345 | 3457 | 436 | 25.2k | |
| Christopher D.�M. Fletcher | 37622 | 13975 | 14085 | 671 | 64.4k | |
| John R. Goldblum | 11009 | 3946 | 9136 | 359 | 20.4k | |
| David S. Klimstra | 10129 | 2133 | 18697 | 486 | 47.2k |
All Works
Login with ORCID to disown or claim papers
Loading papers...